Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 4
1963 4
1964 1
1965 3
1966 1
1967 2
1968 1
1969 3
1970 1
1971 5
1972 2
1973 3
1975 2
1976 1
1977 1
1978 2
1979 4
1980 1
1981 4
1983 3
1984 3
1985 1
1986 6
1987 3
1988 5
1989 5
1990 6
1991 6
1992 10
1993 9
1994 7
1995 10
1996 6
1997 4
1998 4
1999 6
2000 3
2001 3
2002 5
2003 5
2004 4
2005 3
2006 8
2007 6
2008 3
2009 8
2010 3
2011 7
2012 13
2013 13
2014 17
2015 13
2016 14
2017 10
2018 14
2019 19
2020 23
2021 28
2022 36
2023 33
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

408 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: Dipsita
Page 1
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators. Gerstein HC, et al. Lancet. 2019 Jul 13;394(10193):121-130. doi: 10.1016/S0140-6736(19)31149-3. Epub 2019 Jun 9. Lancet. 2019. PMID: 31189511 Clinical Trial.
Continuous-capture microwave imaging.
da Silva FCS, Kos AB, Antonucci GE, Coder JB, Nelson CW, Hati A. da Silva FCS, et al. Nat Commun. 2021 Jun 25;12(1):3981. doi: 10.1038/s41467-021-24219-0. Nat Commun. 2021. PMID: 34172730 Free PMC article.
Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes.
Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD, Lam CSP, Khurmi NS, Heenan L, Del Prato S, Dyal L, Branch K; AMPLITUDE-O Trial Investigators. Gerstein HC, et al. N Engl J Med. 2021 Sep 2;385(10):896-907. doi: 10.1056/NEJMoa2108269. Epub 2021 Jun 28. N Engl J Med. 2021. PMID: 34215025 Clinical Trial.
Assays for Validating Histone Acetyltransferase Inhibitors.
Waddell AR, Liao D. Waddell AR, et al. J Vis Exp. 2020 Aug 6;(162). doi: 10.3791/61289. J Vis Exp. 2020. PMID: 32831305
Inhibitors identified in the HAT assay need to be confirmed in the cellular environment. The ChHAI assay uses immunoblotting to screen for novel HATi that attenuate the robust hyperacetylation of histones induced by a histone deacetylase inhibitor (HDACi). ...Together, the …
Inhibitors identified in the HAT assay need to be confirmed in the cellular environment. The ChHAI assay uses immunoblotting to screen for n …
Clinical Acute Kidney Injury and Histologic Acute Tubular-Interstitial Injury and Their Prognosis in Diabetic Nephropathy.
Lei Q, Xu F, Liang S, Liang D, Lu J, Tang R, Zhou X, Liu Z, Zeng C. Lei Q, et al. Nephron. 2022;146(4):351-359. doi: 10.1159/000520944. Epub 2021 Dec 22. Nephron. 2022. PMID: 34937027
This study aimed to determine the relationship between hATI and clinical acute kidney injury (cAKI) and evaluate significance of hATI in patients with DN. ...CONCLUSION: Our findings indicated that hATI was common in patients with DN where the majorities were …
This study aimed to determine the relationship between hATI and clinical acute kidney injury (cAKI) and evaluate significance of h …
Simplified clinical algorithm for immediate antiretroviral therapy initiation: The HATI [HIV awal (early) Test & Treat in Indonesia] implementation research in Indonesia.
Subronto YW, Kusmayanti NA, Januraga PP, Dewa Wirawan LN, Wisaksana R, Sukmaningrum E, Kawi NH, Iskandar S, Mulyani T, Sulaiman N, Magnani R, Kaldor J, Law M. Subronto YW, et al. Indian J Med Res. 2022 Jun;156(6):729-741. doi: 10.4103/ijmr.ijmr_239_23. Indian J Med Res. 2022. PMID: 37056072 Free PMC article. Review.
INTERPRETATION & CONCLUSIONS: The findings of this study suggest that the HATI-SAI intervention increased the uptake and decreased the time for immediate ART initiation. The HATI-SAI provides a simple and safe clinical approach that can readily be adopted in dif …
INTERPRETATION & CONCLUSIONS: The findings of this study suggest that the HATI-SAI intervention increased the uptake and decrease …
Kala-azar--an enigmatic disease.
Hati AK. Hati AK. Indian J Public Health. 1989 Apr-Jun;33(2):45-54. Indian J Public Health. 1989. PMID: 2701740 Free article. Review.
Polyethylene Glycol 20k. Does It Fluoresce?
Laatsch BF, Brandt M, Finke B, Fossum CJ, Wackett MJ, Lowater HR, Narkiewicz-Jodko A, Le CN, Yang T, Glogowski EM, Bailey-Hartsel SC, Bhattacharyya S, Hati S. Laatsch BF, et al. ACS Omega. 2023 Apr 6;8(15):14208-14218. doi: 10.1021/acsomega.3c01124. eCollection 2023 Apr 18. ACS Omega. 2023. PMID: 37180871 Free PMC article.
Histone acetyltransferase inhibitor II induces apoptosis in glioma cell lines via the p53 signaling pathway.
Xu LX, Li ZH, Tao YF, Li RH, Fang F, Zhao H, Li G, Li YH, Wang J, Feng X, Pan J. Xu LX, et al. J Exp Clin Cancer Res. 2014 Dec 19;33(1):108. doi: 10.1186/s13046-014-0108-3. J Exp Clin Cancer Res. 2014. PMID: 25523932 Free PMC article.
HATi II induced cell cycle arrest at the G2/M phase, and induced significant levels of apoptosis, apoptotic body formation and DNA fragmentation in HATi II-treated U251 and SHG44 cells. ...HATi II deserves further investigation as a novel treatment for glioma …
HATi II induced cell cycle arrest at the G2/M phase, and induced significant levels of apoptosis, apoptotic body formation and DNA fr …
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Botros FT, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators. Gerstein HC, et al. Lancet. 2019 Jul 13;394(10193):131-138. doi: 10.1016/S0140-6736(19)31150-X. Epub 2019 Jun 9. Lancet. 2019. PMID: 31189509 Clinical Trial.
408 results